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Background: With recent improvements in breast imaging, our ability to identify small breast
tumors has markedly improved, prompting significant interest in the use of ablation without surgical
excision to treat early-stage breast cancer. We conducted a multi-institutional pilot safety study of
cryoablation in the treatment of primary breast carcinomas.
Methods: Twenty-nine patients with ultrasound-visible primary invasive breast cancer 2.0 cm
were enrolled. Twenty-seven (93%) successfully underwent ultrasound-guided cryoablation with a
tabletop argon gas–based cryoablation system with a double freeze/thaw cycle. Standard surgical
resection was performed 1 to 4 weeks after cryoablation. Patients were monitored for complications,
and pathology data were used to assess efficacy.
Results: Cryoablation was successfully performed in an office-based setting with only local
anesthesia. There were no complications to the procedure or postprocedural pain requiring narcotic
pain medications. Cryoablation successfully destroyed 100% of cancers 1.0 cm. For tumors
between 1.0 and 1.5 cm, this success rate was achieved only in patients with invasive ductal
carcinoma without a significant ductal carcinoma-in-situ (DCIS) component. For unselected tumors
1.5 cm, cryoablation was not reliable with this technique. Patients with noncalcified DCIS were
the cause of most cryoablation failures.
Conclusions: Cryoablation is a safe and well-tolerated office-based procedure for the ablation of
early-stage breast cancer. At this time, cryoablation should be limited to patients with invasive
ductal carcinoma 1.5 cm and with 25% DCIS in the core biopsy. A multicenter phase II clinical
trial is planned.
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It is estimated that in 2004 there will be more than
215,000 cases of female breast cancer diagnosed in the
United States, making it the most common malignant
tumor in women.1 The most striking influence on the
treatment of breast cancer came after the demonstration
that there was no difference in survival between breast-
conservation therapy and mastectomy.2 This shift in sur-
gical therapy has resulted in a significant decrease in the
morbidity and disfigurement associated with treatment,
without a loss in survival.
A lumpectomy, however, is still an invasive procedure
and leaves the patient with a scar and possible cosmetic
defect in the breast. With improvements in imaging,
cancers smaller than 1.0 cm are increasing in frequency.3
Therefore, there is intense interest in the possibility of
ablating small cancers within the breast without exci-
sional surgery. This not only would improve cosmetic
outcomes, but also could greatly decrease operating
room and anesthesia needs, recovery times, surgical
complications, and health-care costs. Several methods
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are presently being investigated for the in situ ablation of
breast cancer, including radiofrequency ablation,4–7
cryosurgery,8,9 laser interstitial therapy,10–17 high-inten-
sity focused ultrasound,18–25 and focused microwave
thermotherapy.26–29
Cryosurgery has been successfully used for the abla-
tion of tumors in the liver,30,31 prostate,32,33 and kid-
ney34,35; the palliative treatment of locally advanced
breast cancers36,37; and the treatment of breast fibroade-
nomas.38 The ability to clearly visualize the forming ice
ball with ultrasound provides outstanding precision and
control for this procedure. With the recent improvements
in breast imaging, our ability to visualize, take biopsy
samples from, and treat breast tumors has markedly
improved. This has prompted significant interest in the
use of cryoablation instead of surgical excision in the
treatment of small early-stage breast cancer. Preclinical
studies have demonstrated that 100% tumor kill is attain-
able with cryosurgery and that ultrasonography can ac-
curately guide probe placement and monitor the devel-
opment of the ice ball.8,9,39–41 On the basis of these
results, we initiated a phase I multicenter trial of cryoa-
blation followed by delayed surgical excision to deter-
mine the safety and feasibility of this treatment. Prelim-
inary results from this trial reveal that cryoablation of
early-stage breast cancer is extremely well tolerated and
can be performed with minimal discomfort or morbidity.
In addition, with proper patient selection, it can achieve
100% tumor ablation in most patients.
MATERIALS AND METHODS
Cryoablative Procedure
A tabletop argon gas–based cryoablation system
(Visica Cryoablation System; Sanarus Medical, Pleasan-
ton, CA), designed to create probe temperatures of
160°C, was used to treat all tumors in an outpatient
setting (Fig. 1). Ultrasound guidance facilitates accurate
placement of the probe in the center of the tumor. The
cryoablation system creates an ice ball that rapidly en-
gulfs the tumor plus a margin of apparently healthy
tissue. In all cases, patients underwent a double freeze/
thaw cycle: a freeze followed by a passive thaw and then
another freeze. This allows for osmotic shifts to occur at
the cellular level that lead to enhanced destruction of the
targeted tissue.42 An active thaw with helium gas warms
the cryoprobe after the second freeze, permitting its rapid
removal after the last cycle. Over the course of the trial,
the freeze time was altered and the cryoprobe was mod-
ified. The initial probe was a 2.4-mm-diameter, air gap–
insulated, sharp-tipped probe (11 cases). The next-gen-
eration cryoprobe was introduced into the study for cases
12 to 29. It was a 2.7-mm-diameter, vacuum-insulated,
trocar-tipped instrument that allowed cooling to occur
only at its distal 4 cm. The improved insulation on this
probe allowed for elimination of skin protection tech-
niques other than the injection of sterile saline between
the skin and growing ice ball for lesions close to the skin.
Before this probe was introduced, dripped sterile saline,
moist gauze placed between the skin and probe, skin
temperature monitoring, and an introducing trocar with
cannula were additionally used for skin protection.
For the first 11 patients, the freeze time was 10 min-
utes at a 100% duty cycle (argon gas flowing 100% of
the time for maximum cooling) regardless of tumor size.
On the basis of experience treating fibroadenomas,38 this
was subsequently altered so that freeze time was based
on the maximum tumor diameter, as assessed by ultra-
sound, to avoid excessive freezing of uninvolved tissue
around smaller lesions (Table 1). Each freeze cycle was
split between a high freeze and a low freeze. During high
freeze, the system operated at a 100% duty cycle (argon
flowed continuously), whereas during low freeze, it op-
erated at a 10% duty cycle (argon gas flows for 1 second
and is off for 9 seconds of every 10-second period). This
10% duty cycle maintains cold temperatures within the
ice ball while slowing the ice ball’s overall growth. A
passive thaw lasting 10 to 12 minutes (depending on the
FIG. 1. Tabletop argon gas–based cryoablation system.
TABLE 1. Cancer cryoablation
Longest imaged cancer
diameter (cm)
Freeze parameters (minutes at high




a Total treatment  high/low freeze  passive thaw for total time of
high/low freeze  repeat high/low freeze.
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cycle used) was interposed between the two freeze cy-
cles, and an active thaw with helium gas was performed
after the second freeze, thereby facilitating probe
removal.
Clinical Study
Between March 2000 and February 2003, patients
with primary invasive breast cancer at several participat-
ing institutions were offered an opportunity to participate
in a clinical trial involving cryoablation followed by
delayed surgical resection. To be considered for this trial,
all patients had to have ultrasonographic evidence of a
solitary breast mass measuring 2.0 cm in greatest di-
mension. The diagnosis of invasive breast cancer was
made on large-core needle biopsy (LCNB). All standard
histological parameters and immunohistochemical as-
sessment of estrogen and progesterone receptors and
HER-2/neu were established from the core biopsy before
ablation. All participating patients signed written, in-
formed consent that was approved by the institutional
review board of their respective facilities.
Four early cryoablation cases were performed in out-
patient surgery by using general anesthesia1 or intrave-
nous sedation.3 All subsequent cases25 were performed in
an office-based setting without sedation, with the patient
awake and alert throughout the procedure. The breast
was prepared and draped in typical sterile fashion, and
the breast tumor was identified by ultrasonography. Xy-
locaine was injected in the skin and along the projected
path toward the center of the tumor. An 11-blade scalpel
was used to make a 3-mm skin incision to allow place-
ment of the cryoprobe (Fig. 2).
All procedures were performed under real-time ultra-
sound guidance. The probe was inserted through the
center of the cancer, and the tip was advanced beyond the
distal edge of the tumor to ensure equal treatment on
both sides of the tumor in the longitudinal plane of the
freeze zone (Fig. 3). Transverse ultrasound examination
confirmed the central position of the cryoprobe within
the tumor. Failure to adequately place the cryoprobe was
considered a protocol violation. After central placement
within the tumor was confirmed, the cryoablation proce-
dure was performed as described previously. Skin ap-
pearance, ice ball size, and patient comfort were closely
monitored during the procedure. Sterile normal saline
was injected between the forming ice ball and skin when-
ever they were within 5 mm of each other (Fig. 4). After
the second freeze cycle, the probe was actively thawed
and removed, a sterile dressing was applied, and pressure
was maintained according to the institution’s standard
for LCNB. Patients were instructed to look for transient
ecchymosis, tenderness, edema, or a palpable mass in the
region of cryoablation and were asked to report all post-
procedural symptoms.
Within 7 to 30 days of the cryoablation procedure,
patients returned for their planned surgical treatment:
either lumpectomy or mastectomy. Sentinel lymph node
biopsy, when clinically indicated, was performed at the
time of surgical resection. The excised breast specimen
was sent for pathologic evaluation, where the margins
were inked. The tumor was bisected centrally to grossly
determine the dimensions of the region exposed to cryo-
surgery. Radial sections were then submitted for fixation
and histopathological preparation with hematoxylin and
FIG. 3. Ultrasound image of the cryoprobe advanced through the
center of the cancer.
FIG. 2. Cryoablation of breast cancer. Ultrasound is used to monitor
the creation of an ice ball, which engulfs the cancer, destroying the
targeted area.
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eosin staining and were evaluated according to the rou-
tine of the individual institution. These sections were
also assessed to determine the extent of microscopic
destruction of the tumor. A successful ablation was de-
fined as a complete (100%) ablation of the clinically
detectable tumor, including both invasive and in situ
components.
RESULTS
Twenty-nine women participated in the study. The
median age was 52.5 years (range, 34–77 years). The
clinical characteristics of the patients are listed in Table
2. The mean greatest dimension of breast tumors was 1.2
 .5 cm (range, .6–2.0 cm). Distance to the skin ranged
from .2 to 2.0 cm (average, 1.1 cm). The probe was
successfully placed under ultrasound guidance in the
center of the tumor in 27 (93%) of 29 patients. In two
cases, the cryoprobe could not be accurately placed
within the tumor. Of the 27 women successfully treated,
the first 10 patients were treated with 10-minute high-
freeze cycles regardless of tumor size. The next 17
patients underwent tailored ablation with the high/low
freezes previously described. Nine patients with tumors
1.0 cm had two freeze cycles consisting of an 8- or
10-minute high freeze and a 2-minute low freeze. Eight
patients with tumors 1.0 cm underwent two cycles
consisting of a 6-minute high freeze and a 4-minute low
freeze.
Continuous ultrasound monitoring documented the
size of the ice ball forming around the cryoprobe. The
mean dimensions (length  width  depth) of the ice
balls after high-freeze cycles of 8 or 10 minutes was 4. 8
 .7 cm  3.38  .6 cm  3.31  .69 cm. For
high-freeze cycles of 6 minutes, the dimensions were 3.8
 .5 cm  2.7  .5 cm  2.7  .4 cm. The mean
volume of the ice ball was 29.5  13.4 mm3 and 15.2 
5.7 mm3, respectively.
Cryoablation was very well tolerated in all patients.
Early procedures were performed in the operating room,
but 25 procedures were performed in an office-based
setting with only local anesthesia. These patients were
awake and comfortable throughout the freeze-thaw-
freeze cycle, which takes approximately 30 minutes. No
patients had postprocedural pain requiring narcotic pain
medications, and there were no significant complications
from the procedure.
All 27 successfully treated patients underwent
lumpectomy an average of 14 days after the cryoablation
(range, 6 to 30 days). Twenty-five of 27 patients had
axillary staging by intraoperative lymph node mapping
and sentinel lymph node biopsy performed at the same
time. Four (16%) of the 25 patients had a positive sen-
tinel lymph node. The cryoablation had no effect on the
subsequent interpretation of the sentinel lymph node.
Microscopic evaluation showed no viable invasive
cancer in 23 (85%) of the 27 patients who had successful
cryoablation. An additional four patients had ductal car-
cinoma-in-situ (DCIS) present within the normal tissue
surrounding the cryozone. In two cases this was adjacent
to the treatment zone, whereas in two cases this repre-
sented multifocal disease in the healthy tissue surround-
ing the ablation. The likelihood of success of cryoabla-
tion to leave no residual cancer cells was correlated with
tumor size and histology (Table 3). Looking at size
alone, of the 11 patients with tumors 1.0 cm in size
whose tumors were successfully ablated, all 11 had com-
plete ablation of their cancer, with no residual invasive or
intraductal carcinoma. Of the 16 patients with tumors
1.0 cm, 10 (63%) had neither residual invasive carci-
noma or DCIS.
FIG. 4. Injection of saline between the ice ball and skin for skin
protection during cryoablation.










Invasive ductal carcinoma 16 (59%)
Invasive ductal carcinoma with DCIS 5 (19%)
Invasive lobular carcinoma 3 (11%)
Colloid carcinoma 2 (7%)
Medullary carcinoma 1 (3%)
DCIS, ductal carcinoma-in-situ.
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Looking at histology, three patients with invasive lob-
ular carcinoma and two with colloid carcinoma were
treated. Three of these five had residual invasive cancer,
and the final pathology demonstrated the tumor size to be
significantly larger than predicted by pretreatment ultra-
sound. Five patients had invasive cancer and DCIS on
core biopsy. Two of these patients had residual disease
after cryoablation: DCIS alone located outside of the
cryozone in one case and DCIS and invasive cancer at
the treatment edge in the second case. There were 16
patients with invasive ductal carcinoma and 1 with med-
ullary carcinoma. Of these 17 patients, 10 had tumors
1.5 cm. All 10 had complete ablation of their invasive
cancer. One had a residual small focus of DCIS in the
healthy tissue away from the cryozone. Of the seven
patients with invasive ductal carcinoma 1.5 cm, five
(71%) had complete ablation of their cancer, one had
residual invasive disease, and one had residual DCIS at
the periphery.
DISCUSSION
The use of freezing temperatures to treat breast cancer
is not a new concept. More than a century ago, irrigation
devices were designed to bring iced saline solutions in
contact with advanced breast tumors, resulting in the
amelioration of pain and bleeding and a reduction in the
size of the tumor.43–45 Since then there have been several
advances in technology that expanded the applicability
of cryosurgery in the treatment of solid tumors. In 1961,
modern cryosurgery was made possible by the introduc-
tion of automated cryosurgical units that pump liquid
nitrogen through the tip of an instrument, allowing the
cryoablation of tumors at diverse sites, including the
breast. Tanaka37 treated 49 patients with advanced or
recurrent breast cancer with cryosurgery, reporting not
only alleviation of pain, control of hemorrhage, and
reduction of tumor bulk, but also a 5-year survival of
44.4% in this group of “incurable” patients. Rand et
al.41,46 examined the use of cryotherapy performed in
conjunction with surgical excision (cryolumpectomy) for
early-stage cancer. Preclinical studies demonstrated that
this reduced local recurrence, presumably by preventing
the spillage or dissemination of tumor cells as a result of
surgical manipulation. Staren et al.8 explored the concept
of using cryoablation instead of lumpectomy to treat
early-stage breast cancer. Both small- and large-animal
studies demonstrated this to be both feasible and effec-
tive. One patient who opted for cryoablation instead of
surgery remains recurrence free 7 years later.8,47
These results, and the potential benefit of cryosurgery
in the treatment of early-stage breast cancer and devel-
opment of an office-based treatment system, prompted a
phase I multicenter trial of cryoablation followed by
delayed surgical excision. The preliminary results from
this multicenter trial highlight several issues. It is clear
that cryoablation not only is clinically feasible, but also
has minimal pain and morbidity. The subzero tempera-
tures of the ice ball are naturally analgesic, so only local
anesthesia is required for probe placement. Postproce-
dure discomfort was limited to mild edema, ecchymosis,
and tenderness and was well controlled with over-the-
counter medications. Tumor proximity to the skin is not
a contraindication to cryoablation, particularly since the
introduction of the 2.7-mm vacuum-insulated cryoprobe.
The ice ball is extremely well visualized by ultrasound,
and the injection of sterile normal saline easily increases
its distance from the skin. Hyperthermic ablation tech-
niques, in contrast, require a skin distance of at least 1 cm
to avoid the risk of skin injury,7,15 (AN Mirza et al.,
unpublished data) because inadvertent burns have com-
plicated such techniques.5,14
In this study, all patients with tumors 1.0 cm had
complete (100%) ablation of all breast cancer. All pa-
tients with tumors 1.5 cm, excluding those with inva-
sive lobular or colloid carcinoma or significant DCIS,
also had complete ablation (100%) of all breast cancer.
For tumors 1.5 cm, successful cryoablation was not






All patients 27 21 (78%)
Tumors 1.0 cm (all histology) 11 11 (100%)
Tumors 1.0 cm (all histology) 16 10 (63%)
Any size lobular or colloid 5 2 (40%)
Any size ductal with EIC 5 3 (60%)
Any size ductal or medullary, no EIC 17 15 (88%)
Tumors 1.5 cm; ductal or medullary, no EIC 10 10 (100%)
Tumors 1.5 cm; ductal or medullary, no EIC 7 5 (71%)
DCIS, ductal carcinoma-in-situ; EIC, extensive intraductal component.
a Excludes foci of DCIS found in healthy tissue surrounding the treatment zone.
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predictable with these preoperative imaging techniques.
These findings are similar to those described by Pflei-
derer et al.9 in their report of 15 patients with primary
breast tumors treated with cryosurgery. A 1.5-cm size
limit has also been recommended for the use of laser
interstitial therapy and radiofrequency ablation.7,14
These results highlight that the key to ablative tech-
niques is the ability to preoperatively identify truly uni-
focal lesions while being able to visualize both the tumor
and the zone of destruction. With the limitations of
mammography and ultrasonography, tumors without
well-demarcated boundaries should not be treated by in
situ ablation. Invasive lobular carcinomas are often mul-
tifocal or poorly defined on mammography and ultra-
sound, and the extent of the tumor may be substantially
underestimated.49–51 Likewise, mucinous (colloid) carci-
noma is often poorly defined on preoperative imag-
ing.52,53 In this series, of the five patients with either
lobular or mucinous cancer, three had residual invasive
cancer after cryoablation.
On the basis of these results, we recommend that
inclusion for a phase II study of cryoablation without
surgical excision should be limited to patients with in-
vasive ductal carcinoma 1.5 cm and with 25% DCIS
in the aggregate LCNBs. Although tumors 1.5 cm may
eventually be treated with cryoablation, perhaps by either
placing more than one cryoprobe or repositioning the
cryoprobe and performing a second ablation, it will be
necessary to first define a population of patients who can
be treated with simple central placement of a single
cryoprobe. It is also possible that advances in the imag-
ing techniques available today or those in development
might be necessary for the preoperative selection of
patients with more complicated breast cancer in the
future.
The most challenging issue facing all ablative tech-
niques is multifocal noncalcified DCIS. Every attempt
should be made to exclude patients who may have a
significant intraductal component. This includes evi-
dence on LCNB and the presence of microcalcifications
on mammography.54 The extent of microcalcifications
on mammography often underestimates the histological
size of DCIS,55,56 so all tumors with more than just the
most minimal of calcifications present should also be
excluded. However, there were four patients with no
evidence of DCIS on core biopsy or diagnostic imaging
who had DCIS in the periphery of the cryoablated zone.
In two of these cases, this seemed to represent foci of
DCIS in the healthy tissue away from the ablated cancer.
These were detected on wide excision but would not
have been identified if these cancers had been ablated
without surgical excision. Today’s gold standard for
breast-conserving surgery requires the ability to assess
the lumpectomy specimen margins, and, of course, tu-
mor-free margins are required for subsequent optimal
radiotherapy. Before in situ breast cancer ablation can
become a mainstream therapy, the question of margin
assessment will need to be addressed. With no specimen,
how will margin clearance be ensured? Accurate and
predictable preoperative imaging will be necessary to
identify the full extent of disease.
Ultrasound today is unfortunately not accurate enough
to predict the presence and extent of an intraductal com-
ponent.57 Magnetic resonance imaging (MRI) has been
to reported to more accurately diagnose the extent of an
intraductal component than either mammogram or ultra-
sound.58 MRI has been shown to accurately define the
extent of disease in breast cancer, including invasive
lobular tumors,51,58 and has been used to guide ablative
breast procedures.17,21,59 MRI may, therefore, play a fu-
ture role in selecting patients appropriate for in situ
ablation and/or assessing the efficacy of treatment. Fur-
ther research will be necessary to address this issue.
Although there are several obstacles to overcome,
given the potential benefits, there is significant motiva-
tion to identify whether cryoablation can replace lumpec-
tomy in selected patients for the local treatment of small
breast cancers. With the expanding use of screening
mammography, the size of tumors at presentation is
decreasing. Almost two thirds of women who present
with breast cancer today will present with disease local-
ized to the breast,1 and it has been predicted that by the
year 2010, 50% of newly diagnosed breast cancers may
be 1 cm.60 That would represent 90,000 patients for
whom a lumpectomy will be necessary, with the associ-
ated operating room time, anesthesia, cost, and cosmetic
and psychological impact. Compared with lumpectomy,
cryoablation can be performed in an office-based setting
with no IV sedation. Cosmetically, cryosurgery has great
esthetic appeal. It has long been known to cause minimal
scarring when used in the treatment of cancers of the
face, mouth, nose, and cervix.61 Cryoablation of benign
fibroadenomas in the breast is performed with minimal
scarring, outstanding cosmesis, and excellent patient sat-
isfaction.38 Several months after cryosurgery, the
cryotreatment site cannot be identified by ultrasound,
mammogram, or MRI, and this has important conse-
quences for surveillance.39,62
Finally, a unique aspect of cryosurgery that makes it
particularly attractive for in situ ablation is the potential
immunological benefit and the possibility that an im-
mune response generated by the residual tumor protein
material after ablation may be able to inhibit the growth
of tumor foci distant from the primary tumor.63 The
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suggestion that a cryoimmunological benefit may exist
initially came from clinical observations that patients
being treated with cryosurgery showed evidence for an
effect distant from the primary tumor.36,64–66 These ob-
servations prompted several laboratory and clinical stud-
ies that support the notion that cryosurgical destruction
can augment the host’s immune response to tumor tis-
sue.36,67–77 Ongoing research is examining whether
cryoablation of early-stage breast cancer will stimulate a
clinically relevant immune response.
In conclusion, cryoablation can safely and efficiently
treat small primary breast cancers. It can be performed in
an office-based setting with only local anesthesia and
with minimal side effects or discomfort. Ultrasound pro-
vides excellent visualization and control of the ablation
and allows for adequate skin protection so that even
tumors close to the skin can be treated without compli-
cations. Proper patient selection and probe placement is
crucial to successful ablation. Patients with invasive
breast cancer 1.5 cm without invasive lobular or col-
loid cancers or an extensive intraductal component are
good candidates for cryoablation. Assessing margin sta-
tus and the presence of noncalcified DCIS in the healthy-
appearing tissue surrounding the tumor remains a di-
lemma for all ablative technologies. Further research is
necessary to evaluate the most appropriate clinical use of
cryoablation in the treatment of early-stage breast cancer.
REFERENCES
1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics 2004. CA
Cancer J Clin 2004;54:8–29.
2. Fisher B, Redmond C, Poisson R, et al. Eight-year results of a
randomized clinical trial comparing total mastectomy and lumpec-
tomy with or without irradiation in the treatment of breast cancer.
N Engl J Med 1989;320:822–8.
3. Cady B, Stone MD, Schuler JG, et al. The new era in breast cancer:
invasion, size and nodal involvement dramatically decreasing as a
result of mammographic screening. Arch Surg 1996;131:301–8.
4. Jeffrey SS, Birdwell RL, Ikeda DM, et al. Radiofrequency ablation
of breast cancer. First report of an emerging technology. Arch Surg
1999;134:1064–8.
5. Izzo F, Thomas R, Delrio P, et al. Radiofrequency ablation in
patients with primary breast carcinoma. A pilot study in 26 pa-
tients. Cancer 2001;92:2036–44.
6. Singletary SE. Minimally invasive ablation techniques in breast
cancer treatment (editorial). Ann Surg Oncol 2002;9:319–20.
7. Singletary SE, Fornage BD, Sneige N, et al. Radiofrequency ab-
lation of early-stage invasive breast tumors: an overview. Cancer
J 2002;8:177–80.
8. Staren ED, Sabel MS, Gianakakis LM, et al. Cryosurgery of breast
cancer. Arch Surg 1997;132:28–33.
9. Pfleiderer SO, Freesmeyer MG, Marx C, et al. Cryotherapy of
breast cancer under ultrasound guidance: initial results and limita-
tions. Eur Radiol 2002;12:3009–14.
10. Robinson DS, Parel J-M, Denham DB, et al. Interstitial laser
hyperthermia model development for minimally invasive therapy
of breast carcinoma. J Am Coll Surg 1998;186:284–92.
11. Robinson DS, Parel J-M, Denham DB, et al. Stereotactic uses
beyond core biopsy: model development for minimally invasive
treatment of breast cancer through interstitial laser hyperthermia.
Am Surg 1996;62:117–8.
12. Harries SA, Amin Z, Smith ME, et al. Interstitial laser photoco-
agulation as a treatment for breast cancer. Br J Surg 1994;81:
1617–9.
13. Dowlatshahi K, Bauich D, Kluiber R. Histologic evaluation of rat
mammary tumor necrosis by interstitial Nd:YAG laser hyperther-
mia. Lasers Surg Med 1992;12:159–64.
14. Dowlatshahi K, Fan M, Gould VE, et al. Stereotactically guided
laser therapy of occult breast tumors: work in progress report. Arch
Surg 2000;135:1345–52.
15. Dowlatshahi K, Francescatti DS, Bloom KJ. Laser therapy for
small breast cancers. Am J Surg 2002;184:359–63.
16. Mumtaz H, Hall-Graggs MA, Wotherspoon A, et al. Laser therapy
for breast cancer: MR imaging and histopathologic correlation.
Radiology 1996;200:651–8.
17. Harms SE. MR-guided minimally invasive procedures. Magn Re-
son Imaging Clin N Am 2001;9:381–92.
18. Hill CR, ter Haar GR. High intensity focused ultrasound—poten-
tial for cancer treatment. Br J Radiol 1995;68:1296–303.
19. ter Haar GR. Ultrasound focal beam surgery. Ultrasound Med Biol
1995;21:1089–100.
20. Bohris C, Jenne JW, Rastert R, et al. MR monitoring of focused
ultrasound surgery (FUS) in a breast tissue model. Magn Reson
Imaging 2001;19:167–75.
21. Hynynen K, Darkazanli A, Unger E, Schenck JF. MRI-guided
noninvasive ultrasound surgery. Med Phys 1993;20:107–15.
22. Chung AH, Jolesz FA, Hynyen K. Thermal dosimetry of a focused
ultrasound beam in vivo by magnetic resonance imaging. Med
Phys 1999;26:2017–26.
23. Graham SJ, Chen L, Leitch M, et al. Quantifying tissue damage
due to focused ultrasound heating observed by MRI. Magn Reson
Med 1999;41:321–8.
24. Hynynen K, Pomeroy O, Smith DN, et al. MR Imaging-guided
focused ultrasound surgery of fibroadenomas in the breast: a fea-
sibility study. Radiology 2001;219:176–85.
25. Huber PE, Jenne JW, Rastert R, et al. A new non-invasive ap-
proach in breast cancer therapy using magnetic resonance imaging
guided focused ultrasound surgery. Cancer Res 2001;61:8441–7.
26. Chaudhary SS, Mishra RK, Swarup A, Thomas JM. Dielectric
properties of normal and malignant human breast tissue at radio-
wave and microwave frequencies. Indian J Biochem Biophys 1984;
21:76–9.
27. Joines WT, Zhang Y, Li C, Jirtle RL. The measured electrical
properties of normal and malignant human tissues from 50 to 900
MHz. Med Phys 1994;21:547–50.
28. Campbell AM, Land DV. Dielectric properties of female human
breast tissue measured in vitro at 3.2 GHz. Phys Med Biol 1992;
37:193–210.
29. Gardner RA, Vargas HI, Block JB, et al. Focused microwave
phased array thermotherapy for primary breast cancer. Ann Surg
Oncol 2002;9:326–32.
30. Ravikumar TS. The role of cryotherapy in the management of
patients with liver tumors. Adv Surg 1997;30:281–91.
31. Weaver ML, Ashton JG, Zemel R. Treatment of colorectal liver
metastases by cryotherapy. Semin Surg Oncol 1998;14:167–70.
32. Gage AA, Huben R. Cryosurgical ablation of the prostate. Urol
Oncol 2000;5:11–9.
33. Onik GM, Cohen J, Reyes G, et al. Transrectal ultrasound-guided
percutaneous radical cryoablation of the prostate. Cancer 1993;72:
1291–9.
34. Uchida M, Imaide Y, Sugimoto K, et al. Percutaneous cryosurgery
for renal tumors. Br J Urol 1995;75:132–5.
35. Rukstalis D, Khorsandi M, Garcia F, et al. Clinical experience with
renal cryoablation. Urology 2001;57:34–9.
36. Suzuki Y. Cryosurgical treatment of advanced breast cancer and
cryoimmunological responses. Skin Cancer 1995;10:19–26.
548 M. S. SABEL ET AL.
Ann Surg Oncol, Vol. 11, No. 5, 2004
37. Tanaka S. Cryosurgical treatment of advanced breast cancer. Skin
Cancer 1995;10:9–18.
38. Kaufman CS, Bachman B, Littrup PJ, et al. Office-based ultra-
sound-guided cryoablation of breast fibroadenomas. Am J Surg
2002;184:394–400.
39. Rabin Y, Julian TB, Olson P, et al. Long-term follow-up post-
cryosurgery in a sheep breast model. Cryobiology 1999;39:29–46.
40. Rui J, Tatsutani KN, Dahiya R, Rubinsky B. Effect of thermal
variables on human breast cancer in cryosurgery. Breast Cancer
Res Treat 1999;53:185–92.
41. Rand RW, Rand RP, Eggerding FA, et al. Cryolumpectomy for
breast cancer: an experimental study. Cryobiology 1985;22:307–
18.
42. Neel HB, Ketcham AS, Hammond WG. Requisites for successful
cryogenic surgery of cancer. Arch Surg 1971;102:45–8.
43. Gage AA. History of cryosurgery. Semin Surg Oncol 1998;14:99–
109.
44. Bird HM. James Arnott, MD (Aberdeen, 1797–1883): a pioneer in
refrigeration analgesia. Anesthesia 1949;4:10–7.
45. Arnott J. Practical illustrations of the remedial efficacy of a very
low or anesthetic temperature. Lancet 1850;2:257–9.
46. Rand RW, Rand RP, Eggerding F, et al. Cryolumpectomy for
carcinoma of the breast. Surg Gynecol Obstet 1987;165:392–6.
47. Simmons R, Dowlatshahi K, Singletary SE, Staren ED. Image-
guided ablation of breast tumors. Contemp Surg 2002;58:61–71.
48. Deleted in proof.
49. Helvie MA, Paramagul C, Oberman HA, Adler DD. Invasive
lobular carcinoma: imaging features and clinical detection. Invest
Radiol 1993;28:202–7.
50. Krecke KN, Gisvold JJ. Invasive lobular carcinoma of the breast:
mammographic findings and extent of disease at diagnosis in 183
patients. AJR Am J Roentgenol 1993;61:957–60.
51. Munot K, Dall B, Achuthan R, et al. Role of magnetic resonance
imaging in the diagnosis and single-stage surgical resection of
invasive lobular carcinoma of the breast. Br J Surg 2002;89:1296–
301.
52. Chopra S, Evans AJ, Pinder SE, et al. Pure mucinous breast
cancer—mammographic and ultrasound findings. Clin Radiol
1996;51:421–4.
53. Wilson TE, Helvie MA, Oberman HA, et al. Pure and mixed
mucinous carcinoma of the breast: pathological basis for differ-
ences in mammographic appearance. AJR Am J Roentgenol 1995;
165:285–9.
54. Stomper PC, Connolly JL. Mammographic features predicting an
extensive intraductal component in early stage infiltrating ductal
carcinoma. AJR Am J Roentgenol 1992;158:269–72.
55. Satake H, Shimamoto K, Sawaki A, et al. Role of ultrasonography
in the detection of intraductal spread of breast cancer: correlation
with pathologic findings, mammography and MR imaging. Eur
Radiol 2000;10:1726–32.
56. Holland R, Hendriks JH, Verbeek A, et al. Extent, distribution, and
mammographic/histologic correlations of breast ductal carcinoma
in situ. Lancet 1990;335:519–22.
57. Tresserra F, Feu J, Grases PJ, et al. Assessment of breast cancer
size: sonographic and pathologic correlation. J Clin Ultrasound
1999;27:485–91.
58. Boetes C, Mus RD, Holland R, et al. Breast tumors: comparative
accuracy of MR imaging relative to mammography and US for
demonstrating extent. Radiology 1995;197:743–7.
59. Deleted in proof.
60. Cady B. Breast cancer in the third millennium. Breast J 2000;6:
280–7.
61. Shepherd JP, Dawber RPR. Wound healing and scarring after
cryosurgery. Cryobiology 1984;21:157–69.
62. Deleted in proof.
63. Johnson JP. Immunologic aspects of cryosurgery: potential mod-
ulation of immune recognition and effector cell maturation. Clin
Dermatol 1990;8:39–47.
64. Gage AA. Cryosurgery for oral and pharyngeal carcinoma. Am J
Surg 1969;118:669–72.
65. Soanes WA, Ablin RJ, Gonder MJ. Remission of metastatic lesions
following cryosurgery in prostatic cancer. J Urol 1970;104:154–9.
66. Ablin RJ. An appreciation and realization of the concept of cryo-
immunology. In: Ablin RJ, ed. Percutaneous Prostate Cryoabla-
tion. St. Louis: Quality Medical Publishing Inc, 1995:136–54.
67. Bayjoo P, Rees RC, Goepel JR, Jacob G. Natural killer cell activity
following cryosurgery of normal and tumour bearing liver in an
animal model. J Clin Lab Immunol 1991;35:129–32.
68. Bilchik AJ, Sarantou T, Wardlaw JC, Ramming KP. Cryosurgery
causes a profound reduction in tumor markers in hepatoma and
noncolorectal hepatic metastases. Am Surg 1997;63:796–800.
69. Faraci RP, Bagley DH, Marrone JC, Beazley RM. The effect of
curative cryosurgery on the tumor-specific immune response of
C57 mice. Cryobiology 1975;12:175–9.
70. Fazio M, Airoldi M, Gandolfo S, et al. Humoral and cellular
immune response to cryosurgery of benign and malignant lesions
of the oral cavity (in Italian). Boll Soc Ital Biol Sper 1982;58:
412–8.
71. Faraci RP, Bagley DH, Marrone JC, Beazley RM. In vitro deter-
mination of cryosurgical augmentation of tumor immunity. Sur-
gery 1975;77:433–8.
72. Hoffmann NE, Coad JE, Huot CS, et al. Investigation of the
mechanism and the effect of cryoimmunology in the Copenhagen
rat. Cryobiology 2001;41:59–68.
73. Kogel H, Grundmann R, Fohlmeister I, Pichlmaier H. Cryotherapy
of rectal cancer. Immunologic results (in German). Zentralbl Chir
1985;110:147–54.
74. Misao A, Sakata K, Saji S, Kuneida T. Late appearance of resis-
tance to tumor rechallenge following cryosurgery: a study in an
experimental mammary tumor of the rat. Cryobiology 1981;18:
386–9.
75. Tsujino M. Activation and regulation of macrophages induced by
inoculation of cryodestroyed tumor cells (in Japanese). Osaka
Daigaku Shigaku Zasshi 1990;35:180–205.
76. Wang Z. Cryosurgery in rectal carcinoma—report of 41 cases (in
Chinese). Zhonghua Zhong Liu Za Zhi 1989;11:226–7.
77. Ravindranath MH, Wood TF, Soh D, et al. Cryosurgical ablation of
liver tumors in colon cancer patients increases the serum total
ganglioside level and then selectively augments antiganglioside
IgM. Cryobiology 2002;45:10–21.
549CRYOABLATION OF BREAST CANCER
Ann Surg Oncol, Vol. 11, No. 5, 2004
